Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  > SCHEME PROFILE
SCHEME PROFILE      
AMC : Category : Scheme :
Nippon India Nifty Pharma ETF
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited21.29261344676214.5162
Domestic EquitiesDivi's Laboratories Limited9.691616136297.6401
Domestic EquitiesCipla Limited9.389771449094.5985
Domestic EquitiesDr. Reddy's Laboratories Limited9.356777387194.2652
Domestic EquitiesLupin Limited6.578330784966.2737
Domestic EquitiesTorrent Pharmaceuticals Limited5.222113282852.6105
Domestic EquitiesLaurus Labs Limited4.726049340147.6132
Domestic EquitiesAurobindo Pharma Limited4.257835519042.8963
Domestic EquitiesAlkem Laboratories Limited4.18727430242.1850
Domestic EquitiesGlenmark Pharmaceuticals Limited3.826619124038.5521
Domestic EquitiesBiocon Limited3.298990608833.2353
Domestic EquitiesMankind Pharma Limited3.028314364130.5093
Domestic EquitiesZydus Lifesciences Limited2.792531777928.1330
Domestic EquitiesIPCA Laboratories Limited2.576817650225.9599
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited1.926810383719.4123
Domestic EquitiesGland Pharma Limited1.852510106918.6634
Domestic EquitiesAbbott India Limited1.8137662918.2728
Domestic EquitiesAjanta Pharma Limited1.47725349714.8823
Domestic EquitiesWockhardt Limited1.439110489414.4984
Domestic EquitiesPiramal Pharma Limited1.206478577812.1544
Total 99.9410 1006.8719
Cash & Cash Equivalents and Net AssetsTriparty Repo0.1867 1.8811
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0000 0.0005
Cash & Cash Equivalents and Net AssetsNet Current Assets-0.1278 -1.2871
Total 0.0590 0.5945
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.